- Home
- TPCS vs EXEL Comparison
TPCS vs EXEL Comparison
Compare TPCS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPCS
- EXEL
- Stock Information
- Founded
- TPCS 1956
- EXEL 1994
- Country
- TPCS United States
- EXEL United States
- Employees
- TPCS N/A
- EXEL N/A
- Industry
- TPCS Metal Fabrications
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TPCS Industrials
- EXEL Health Care
- Exchange
- TPCS Nasdaq
- EXEL Nasdaq
- Market Cap
- TPCS N/A
- EXEL 9.8B
- IPO Year
- TPCS N/A
- EXEL 2000
- Fundamental
- Price
- TPCS $3.34
- EXEL $36.73
- Analyst Decision
- TPCS
- EXEL Buy
- Analyst Count
- TPCS 0
- EXEL 18
- Target Price
- TPCS N/A
- EXEL $37.59
- AVG Volume (30 Days)
- TPCS 39.7K
- EXEL 2.3M
- Earning Date
- TPCS 04-08-2025
- EXEL 05-13-2025
- Dividend Yield
- TPCS N/A
- EXEL N/A
- EPS Growth
- TPCS N/A
- EXEL 170.77
- EPS
- TPCS N/A
- EXEL 1.76
- Revenue
- TPCS $33,154,058.00
- EXEL $2,168,701,000.00
- Revenue This Year
- TPCS N/A
- EXEL $5.78
- Revenue Next Year
- TPCS N/A
- EXEL $10.94
- P/E Ratio
- TPCS N/A
- EXEL $20.74
- Revenue Growth
- TPCS 8.71
- EXEL 18.50
- 52 Week Low
- TPCS $2.05
- EXEL $20.14
- 52 Week High
- TPCS $4.99
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- TPCS 73.25
- EXEL 49.28
- Support Level
- TPCS $2.83
- EXEL $34.90
- Resistance Level
- TPCS $3.29
- EXEL $40.26
- Average True Range (ATR)
- TPCS 0.17
- EXEL 1.18
- MACD
- TPCS 0.09
- EXEL -0.13
- Stochastic Oscillator
- TPCS 94.00
- EXEL 40.67
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.